Day: August 3, 2021

OperationalThe fleet utilisation rate in the second quarter of 2021 was 65.8 per cent (Q2 2020: 6.5 per cent). Safe Zephyrus continued the contract for Shell at the Shearwater platform in the UK and was in full operation throughout the quarter. The contract initially had a firm period of 145 days and has to date been extended by the client by additional 16 days. Safe Caledonia has been operating for TotalEnergies at the Elgin platform in the UK since 30 March 2021 and was fully utilised in the quarter. The contract has a firm duration of 162 days and two 15-day options, of which the first available option was exercised on 29 July 2021. Safe Boreas has been operating for CNOOC at Buzzard in the UK since 20 April 2021. After two of the three 30-day options were exercised on 9 July 2021, the contract now has a firm duration of 160 days. ...

GENEVA, Switzerland August 3, 2021 – ObsEva SA (NASDAQ: OBSV; SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health, today announced that Company Management will provide a corporate update at the Wedbush PacGrow Healthcare Conference to be held August 10-11, 2021 and the Canaccord Genuity 41st Annual Growth Conference to be held August 10-12, 2021. Details on the presentations can be found below.   Wedbush PacGrow Healthcare Conference Date: Wednesday, August 11, 2021Presentation Time: 8 a.m. ESTWebcast: Click Here   Canaccord Genuity 41st Annual Growth Conference Date: Thursday, August 12, 2021Presentation Time: 9 a.m. ESTWebcast: Click Here The presentations and archived webcasts will also be accessible under “Events Calendar” in the investors section...

SpareBank 1 SMN is presenting 2nd quarter 2021 financial results. Time:    Thursday 12 August at 08:00 AM CETPlace:    Webinar Please register by 11 August on the link below: http://epost.sparebank1.no/public/event/RegistrationForm/424B5C477547425D457940 The presentation will be held in Norwegian by group CEO Jan-Frode Janson and CFO Kjell Fordal. We will also host a Global Investor Webinar in English on the same day at 3:15 PM CET. Please register by 11 August on the following link: http://epost.sparebank1.no/public/event/RegistrationForm/424B5C477549455D477440 Questions to the management in relation to both presentations can be sent to ir@smn.no. The results will be published on 12 August at 7:00 AM CET. This information is subject of the disclosure requirements acc. to §5-12 vphl (Norwegian Securities Trading Act)

Application is being reviewed under the US FDA’s Real-Time Oncology Review pilot programme Based on results of the Phase III IMpower010 study, presented at ASCO, that showed adjuvant Tecentriq improved disease-free survival by more than one-third in PD-L1-positive early-stage lung cancer, compared with best supportive care Tecentriq is the first and only cancer immunotherapy to demonstrate positive Phase III results in the adjuvant lung cancer settingBasel, 3 August 2021 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the US Food and Drug Administration (FDA) has accepted the company’s supplemental Biologics License Application (sBLA) and granted Priority Review for Tecentriq® (atezolizumab) as adjuvant treatment following surgery and platinum-based chemotherapy for people with non-small cell lung cancer (NSCLC) whose...

Sanofi to acquire Translate Bio; advances deployment of mRNA technology across vaccines and therapeutics development Accelerates development of current Sanofi licensed programs in vaccines and potential to explore other therapeutic areas Fast tracks establishment of Sanofi’s recently announced mRNA Center of Excellence Full integration upgrades drug formulation capabilities and enhances US talent in a promising new technologyPARIS and LEXINGTON, Mass – August 3, 2021 – As part of Sanofi’s endeavor to accelerate the application of messenger RNA (mRNA) to develop therapeutics and vaccines, the company has entered into a definitive agreement with Translate Bio (NASDAQ: TBIO), a clinical-stage mRNA therapeutics company, under which Sanofi will acquire all outstanding shares of Translate Bio for $38.00 per share in cash, which represents...

ANG-3070 was well-tolerated across dose cohorts, achieving drug exposures in humans exceeding exposures in which activity was demonstrated in animal models of proteinuric kidney diseases Pharmacokinetic data potentially supportive of once-daily dosing An international Phase 2 trial in patients with primary proteinuric kidney diseases will begin enrolling patients in the second half of this year Company to host a Virtual Fibrosis R&D Day on September 20, 2021UNIONDALE, N.Y., Aug. 03, 2021 (GLOBE NEWSWIRE) — Angion Biomedica Corp (NASDAQ:ANGN), a late-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel small molecule therapeutics to address acute organ injuries and fibrotic diseases, today announced positive results from its Phase 1 study in healthy volunteers for ANG-3070,...

Oslo, 3 August 2021 – DNO ASA, the Norwegian oil and gas operator, today announced that the Kurdistan Regional Government has approved the Company’s acquisition of ExxonMobil’s remaining 32 percent interest in the Baeshiqa license, doubling DNO’s stake. In parallel, commerciality has been declared on the license with plans submitted for fast-track development including early production from previously drilled but suspended wells. DNO has already demonstrated proof of concept of producing these wells through temporary test facilities, having trucked some 15,000 barrels of 40 degree API and 22 degree API oil for export in 2019 and 2020 from the Baeshiqa-2 and Zartik-1 discovery wells. Following the transaction, the joint venture comprises DNO as operator with a 64 percent (80 percent paying) interest, the Turkish Energy Company (TEC) with...

JERICHO, NY, Aug. 02, 2021 (GLOBE NEWSWIRE) — via NewMediaWire — Paltalk, Inc., (“Paltalk,” the “Company,” “we,” “our” or “us”) (OTCQB: PALT), a leading communications software innovator that powers multimedia social applications, today announced the pricing of its underwritten public offering of 1,159,400 shares of common stock at a price to the public of $3.00 per share. The shares of common stock are expected to begin trading on The Nasdaq Capital Market, on August 3, 2021, under the symbol “PALT”.  Paltalk expects to receive gross proceeds of approximately $3.5 million, before deducting underwriting discounts and commissions and other estimated offering expenses.  The Company has granted the underwriter a 45-day option to purchase an additional 173,910 shares of common stock at the public offering price per share,...

ST. LOUIS, Aug. 02, 2021 (GLOBE NEWSWIRE) — Huttig Building Products, Inc. (“Huttig”) (NASDAQ: HBP), a leading domestic distributor of millwork, building materials, and wood products, announced today that one of Huttig’s board members was recognized for her role in corporate governance. Gina Hoagland, a member of Huttig Building Products’ Board of Directors, was recognized as a 2021 Director to Watch by Directors & Boards, a publication focused on corporate governance. Directors to Watch was first launched in 2006 and annually features leading women directors who make an impact on public company boards. “We’re honored to have Gina Hoagland on our board of directors and applaud her for this well-deserved recognition from Directors & Boards,” Jon Vrabely, President & Chief Executive Officer, said. Gina chairs the Nominating...